Slatkin M, Bertorelle G
Department of Integrative Biology, University of California, Berkeley, CA 94720-3140, USA.
Genetics. 2001 Jun;158(2):865-74. doi: 10.1093/genetics/158.2.865.
To better understand the forces affecting individual alleles, we introduce a method for finding the joint distribution of the frequency of a neutral allele and the extent of variability at closely linked marker loci (the intraallelic variability). We model three types of intraallelic variability: (a) the number of nonrecombinants at a linked biallelic marker locus, (b) the length of a conserved haplotype, and (c) the number of mutations at a linked marker locus. If the population growth rate is known, the joint distribution provides the basis for a test of neutrality by testing whether the observed level of intraallelic variability is consistent with the observed allele frequency. If the population growth rate is unknown but neutrality can be assumed, the joint distribution provides the likelihood of the growth rate and leads to a maximum-likelihood estimate. We apply the method to data from published data sets for four loci in humans. We conclude that the Delta32 allele at CCR5 and a disease-associated allele at MLH1 arose recently and have been subject to strong selection. Alleles at PAH appear to be neutral and we estimate the recent growth rate of the European population to be approximately 0.027 per generation with a support interval of (0.017-0.037). Four of the relatively common alleles at CFTR also appear to be neutral but DeltaF508 appears to be significantly advantageous to heterozygous carriers.
为了更好地理解影响单个等位基因的作用力,我们引入了一种方法来确定中性等位基因频率与紧密连锁标记位点处的变异程度(等位基因内变异)的联合分布。我们对三种类型的等位基因内变异进行建模:(a) 连锁双等位基因标记位点处的非重组体数量,(b) 保守单倍型的长度,以及 (c) 连锁标记位点处的突变数量。如果种群增长率已知,联合分布为通过检验观察到的等位基因内变异水平是否与观察到的等位基因频率一致来进行中性检验提供了基础。如果种群增长率未知但可以假设为中性,联合分布提供了增长率的似然性并得出最大似然估计值。我们将该方法应用于来自已发表的人类四个基因座数据集的数据。我们得出结论,CCR5 基因座上的 Delta32 等位基因和 MLH1 基因座上的一个疾病相关等位基因是最近出现的,并且受到了强烈的选择。PAH 基因座上的等位基因似乎是中性的,我们估计欧洲人群最近的增长率约为每代 0.027,支持区间为 (0.017 - 0.037)。CFTR 基因座上四个相对常见的等位基因似乎也是中性的,但 DeltaF508 对杂合携带者似乎具有显著优势。